Loading...
XNASNAOV
Market cap2mUSD
Dec 24, Last price  
0.54USD
Name

Nanovibronix Inc

Chart & Performance

D1W1MN
XNAS:NAOV chart
P/E
—
P/S
0.88
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
40.26%
Rev. gr., 5y
48.33%
Revenues
2m
+203.59%
94,000166,000211,000203,000147,000229,000239,000318,000530,000623,0001,695,000752,0002,283,000
Net income
-4m
L-31.88%
-723,000-1,275,000-1,989,000-2,647,000-2,884,000-2,831,000-4,965,000-4,154,000-5,794,000-4,326,000-14,282,000-5,448,000-3,711,000
CFO
-4m
L-48.80%
-547,000-787,000-602,000-900,000-1,480,000-1,533,000-2,182,000-3,550,000-3,874,000-3,391,000-4,367,000-7,035,000-3,602,000
Earnings
May 13, 2025

Profile

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
URL
https://nanovibronix.com/
IPO date
Apr 24, 2015
Employees
9
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,283
203.59%
752
-55.63%
1,695
172.07%
Cost of revenue
5,719
5,764
7,378
Unusual Expense (Income)
NOPBT
(3,436)
(5,012)
(5,683)
NOPBT Margin
Operating Taxes
29
35
32
Tax Rate
NOPAT
(3,465)
(5,047)
(5,715)
Net income
(3,711)
-31.88%
(5,448)
-61.85%
(14,282)
230.14%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,215
2,090
4,968
BB yield
-209.43%
-584.20%
-379.68%
Debt
Debt current
10
81
49
Long-term debt
5
162
49
Deferred revenue
15
107
153
Other long-term liabilities
217
142
253
Net debt
(3,268)
(2,473)
(7,658)
Cash flow
Cash from operating activities
(3,602)
(7,035)
(4,367)
CAPEX
(1,000)
(3)
(3)
Cash from investing activities
(1,000)
(3)
(3)
Cash from financing activities
4,222
2,092
4,580
FCF
(4,091)
(5,139)
(5,734)
Balance
Cash
3,283
2,713
7,737
Long term investments
3
19
Excess cash
3,169
2,678
7,671
Stockholders' equity
(66,161)
(62,401)
(56,849)
Invested Capital
70,391
66,045
63,617
ROIC
ROCE
EV
Common stock shares outstanding
1,750
1,420
1,258
Price
1.15
356.35%
0.25
-75.77%
1.04
36.11%
Market cap
2,013
462.57%
358
-72.66%
1,308
232.57%
EV
(1,255)
(2,115)
(6,350)
EBITDA
(3,435)
(5,011)
(5,681)
EV/EBITDA
0.37
0.42
1.12
Interest
246
347
Interest/NOPBT